N-tert-butyl-2,6-dimethylaniline

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-tert-butyl-2,6-dimethylaniline
• 化学式: C₁₂H₁₉N
• 分子量: 177.29
• InChiKey: KMESIPKMPAFFOH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  十一烷 在 potassium tert-butylate 作用下， 生成 N-tert-butyl-2,6-dimethylaniline
  参考文献：
  名称：

  ORGANOMETALLIC COMPOUNDS

  摘要：

  The invention relates to new processes for preparing palladium complexes, allowing preparation of known products with high purity and in good yields and also allowing preparation of new palladium complexes. The invention also relates to new palladium complexes that are suitable as precatalysts and/or catalysts, in particular for coupling reactions.

  公开号：

  US20240116965A1

文献信息

• Sterically Hindered Amination of Aryl Chlorides Catalyzed by a New Carbazolyl-Derived P,N-Ligand-Composed Palladium Complex
  作者：Wing In Lai、Man Pan Leung、Pui Ying Choy、Fuk Yee Kwong

  DOI：10.1055/s-0037-1611534

  日期：2019.7

  ‡ These authors contributed equally to this work. Published as part of the Special Topic Amination Reactions in Organic Synthesis Abstract A family of 2-(9H-carbazol-9-yl)phenyl-based phosphine ligands were synthesized and their efficacy in promoting the steric hindered Buchwald–Hartwig amination was evaluated. In the presence of Pd(OAc)2 (0.03–1.0 mol%) associated with the newly developed a carbazolyl-derived

  ‡这些作者对这项工作做出了同等的贡献。 作为有机合成中的特殊主题胺化反应的一部分发布 抽象的 合成了一个基于2-（9 H-咔唑-9-基）苯基的膦配体家族，并评估了它们在促进空间受阻的布赫瓦尔德-哈特维格胺胺化中的功效。在新开发的咔唑基膦配体与Pd（OAc）2（0.03-1.0 mol％）存在的情况下，四邻位取代的二芳基胺的合成进展顺利，产品收率极高（高达99％）。即使将高度空间拥挤的2,6-二异丙基苯胺与受阻的2-氯-1,3,5-三异丙基苯偶合（分离产率为96％），也获得了显着结果。还报道了蒽基C–N偶联产物的可能分解途径。 合成了一个基于2-（9 H-咔唑-9-基）苯基的膦配体家族，并评估了它们在促进空间受阻的布赫瓦尔德-哈特维格胺胺化中的功效。在新开发的咔唑基膦配体与Pd（OAc）2（0.03-1.0 mol％）存在的情况下，四邻位取代的二芳基胺的合成进展顺利，产品收率极高（高达99％）。即使将高度空间拥挤的2
• Copper-Catalyzed N-tert-Butylation of Aromatic Amines under Mild Condi­tions Using tert-Butyl 2,2,2-Trichloroacetimidate
  作者：John Cran、Dinesh Vidhani、Marie Krafft

  DOI：10.1055/s-0033-1339107

  日期：——

  A variety of aromatic amines have been found to expediently undergo copper-catalyzed N-tert-butylation in the presence of tert-butyl 2,2,2-trichloroactimidate at room temperature.

  已经发现，在室温下，在 2,2,2-三氯亚胺酸叔丁酯存在下，多种芳香胺可以方便地进行铜催化的 N-叔丁基化反应。
• Halogen‐Bridged Methylnaphthyl Palladium Dimers as Versatile Catalyst Precursors in Coupling Reactions
  作者：Nardana Sivendran、Nico Pirkl、Zhiyong Hu、Angelino Doppiu、Lukas J. Gooßen

  DOI：10.1002/anie.202110450

  日期：2021.11.15

  Halide-bridged 1- and 2-methylnaphthyl palladium dimers are presented as convenient, yet highly efficient palladium sources for cross-coupling catalysis. The bench-stable complexes smoothly react with various ligands yielding monoligated palladium precatalysts. These display record-setting activity in various catalytic reactions, clearly beyond that achievable by ligand screening alone.

  卤化物桥接的 1-和 2-甲基萘基钯二聚体被认为是用于交叉偶联催化的方便且高效的钯源。台架稳定的配合物与各种配体顺利反应，产生单配位钯预催化剂。这些在各种催化反应中显示出创纪录的活性，明显超出了仅通过配体筛选所能达到的水平。
• Efficient palladium catalysts for the amination of aryl chlorides: a comparative study on the use of phosphium salts as precursors to bulky, electron-rich phosphines
  作者：Amit Tewari、Martin Hein、Alexander Zapf、Matthias Beller

  DOI：10.1016/j.tet.2005.06.067

  日期：2005.10

  phonium salts are practical ligand precursors for the palladium-catalyzed amination of aryl chlorides. In the presence of typically 0.5 mol% Pd(OAc)2 and 1 mol% of ligand precursor a variety of activated and deactivated aryl chlorides can be aminated in good to excellent yield (73–99%). Applying optimized conditions catalyst turnover numbers up to 10,000 have been achieved.

  烷基二-（1-金刚烷基）salts盐是钯催化芳基氯化物胺化的实用配体前体。在通常存在0.5 mol％的Pd（OAc）2和1 mol％的配体前体的情况下，各种活化和失活的芳基氯化物都可以胺化，收率良好至极佳（73-99％）。采用优化条件，催化剂的周转量已达到10,000。
• Spiropyrrolidine derived antiviral agents
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US11339170B1

  公开（公告）日：2022-05-24

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

  本发明揭示了式（I）的化合物及其药学上可接受的盐：可抑制冠状病毒复制活性。本发明还涉及包含式（I）的化合物或其药学上可接受的盐的制药组合物，以及治疗或预防受冠状病毒感染的患者的方法，包括向患者施用式（I）的化合物或其药学上可接受的盐的治疗有效量。